Pipeline

Our VAL-083 in Development

DelMar Pharmaceuticals is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.

Other
Pre-clinical Phase 1 Phase 2 Phase 3 NDA
Single Agent: Recurrent TMZ-resistant (MDACC) MGMT-unmethylated GBM
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NDA Phase not started
Combination with XRT: Newly Diagnosed (Sun Yat-sen University) MGMT-unmethylated GBM
Pre-clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NDA Phase not started
Ovarian cancer
Pre-clinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
NDA Phase not started
Pediatric Brain Tumor
Pre-clinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
NDA Phase not started

VAL-083 Shows Potential Against Multiple Cancers

Our lead candidate, VAL-083, is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.

VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studies in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.

We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.

View Candidate

Explore Our Scientific Publications & Presentations

Dive deeper into our work by reviewing our robust catalog of scientific publications and presentations.

View Publications and Presentations